Sylvie Grégoire
Director/Board Member at NOVO NORDISK A/S
Net worth: 2 M $ as of 2024-03-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| John Alam | M | 62 |
EIP Pharma, Inc.
 EIP Pharma, Inc. BiotechnologyHealth Technology EIP Pharma, Inc. engages in the research and development of therapeutic drugs for the central nervous system disorders. It focuses on neflamapimod, which is a clinical-stage oral investigational drug for the treatment of brain diseases such as Alzheimer?s disease and for non-brain disorders including rheumatoid arthritis. The company was founded by John Alam and Sylvie Louise Gregorie and is headquartered in Cambridge, MA. | 21 years |
| Helge Lund | M | 61 | 9 years | |
| Lars Fruergaard Jorgensen | M | 58 | 33 years | |
| Samuel Chapin | M | 66 |
Revvity BV
 Revvity BV Medical SpecialtiesHealth Technology PerkinElmer focuses on improving the health and safety of people and the environment. The company is headquartered in Zaventem, Belgium. | 8 years |
| Tatjana Anni Hilde May | F | 58 |
Shire Plc /Old/
 Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986
Shire Orphan Therapies GmbH
 Shire Orphan Therapies GmbH Pharmaceuticals: MajorHealth Technology Shire Orphan Therapies GmbH engages in the development, manufacture, and distribution of chemical and biochemical products, ingredients, as well as pharmaceutical and diagnostic products. The company was founded in 1994 and is headquartered in Berlin, Germany. | 8 years |
| Tajinder Vohra | M | 58 |
Revvity BV
Revvity BV Medical SpecialtiesHealth Technology PerkinElmer focuses on improving the health and safety of people and the environment. The company is headquartered in Zaventem, Belgium. | 9 years |
| Pascale Witz | F | 57 |
Revvity BV
Revvity BV Medical SpecialtiesHealth Technology PerkinElmer focuses on improving the health and safety of people and the environment. The company is headquartered in Zaventem, Belgium. | 7 years |
| Frank R. Witney Witney | M | 70 |
Revvity BV
Revvity BV Medical SpecialtiesHealth Technology PerkinElmer focuses on improving the health and safety of people and the environment. The company is headquartered in Zaventem, Belgium. | 8 years |
| Prahlad Singh | M | 59 |
Revvity BV
Revvity BV Medical SpecialtiesHealth Technology PerkinElmer focuses on improving the health and safety of people and the environment. The company is headquartered in Zaventem, Belgium. | 10 years |
| Michel Vounatsos | M | 62 |
Revvity BV
Revvity BV Medical SpecialtiesHealth Technology PerkinElmer focuses on improving the health and safety of people and the environment. The company is headquartered in Zaventem, Belgium. | 4 years |
| Robert Cobuzzi | M | 60 | 1 years | |
| Saiyed Mahmood | M | 48 |
F2G Ltd.
 F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | - |
| Andreas Fibig | M | 62 | 6 years | |
| William Elder | M | 41 | 1 years | |
| Madhav Devalaraja | M | 59 |
Corvidia Therapeutics, Inc.
 Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | 9 years |
| Laurence Debroux | F | 54 | 5 years | |
| Henrik Ehlers Wulff | M | 54 | 25 years | |
| Karsten Munk Knudsen | M | 53 | 25 years | |
| Martin Hermanus Soeters | M | 70 | 18 years | |
| Jeffrey Poulton | M | 56 |
EIP Pharma, Inc.
EIP Pharma, Inc. BiotechnologyHealth Technology EIP Pharma, Inc. engages in the research and development of therapeutic drugs for the central nervous system disorders. It focuses on neflamapimod, which is a clinical-stage oral investigational drug for the treatment of brain diseases such as Alzheimer?s disease and for non-brain disorders including rheumatoid arthritis. The company was founded by John Alam and Sylvie Louise Gregorie and is headquartered in Cambridge, MA. | 1 years |
| Marwan Noel Sabbagh | M | 58 |
EIP Pharma, Inc.
EIP Pharma, Inc. BiotechnologyHealth Technology EIP Pharma, Inc. engages in the research and development of therapeutic drugs for the central nervous system disorders. It focuses on neflamapimod, which is a clinical-stage oral investigational drug for the treatment of brain diseases such as Alzheimer?s disease and for non-brain disorders including rheumatoid arthritis. The company was founded by John Alam and Sylvie Louise Gregorie and is headquartered in Cambridge, MA. | 3 years |
| Patrick Volkert Vink | M | 60 |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | 8 years |
| Christina Law | F | 57 | 2 years | |
| John H. Rex | M | - |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | - |
| Michelle McMurry-Heath | M | 54 | 2 years | |
| Francesco Maria Lavino | M | 51 |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | 3 years |
| Maxwell Krakowiak | M | 35 | 6 years | |
| Martin MacKay | M | 68 | 6 years | |
| Marcus Schindler | M | 57 | 6 years | |
| William Tanner | M | 66 |
EIP Pharma, Inc.
EIP Pharma, Inc. BiotechnologyHealth Technology EIP Pharma, Inc. engages in the research and development of therapeutic drugs for the central nervous system disorders. It focuses on neflamapimod, which is a clinical-stage oral investigational drug for the treatment of brain diseases such as Alzheimer?s disease and for non-brain disorders including rheumatoid arthritis. The company was founded by John Alam and Sylvie Louise Gregorie and is headquartered in Cambridge, MA. | 1 years |
| Susan Alexander | F | 67 | 21 years | |
| Yi Ping Lin | F | - | 1 years | |
| Frank Zavrl | M | 58 |
EIP Pharma, Inc.
EIP Pharma, Inc. BiotechnologyHealth Technology EIP Pharma, Inc. engages in the research and development of therapeutic drugs for the central nervous system disorders. It focuses on neflamapimod, which is a clinical-stage oral investigational drug for the treatment of brain diseases such as Alzheimer?s disease and for non-brain disorders including rheumatoid arthritis. The company was founded by John Alam and Sylvie Louise Gregorie and is headquartered in Cambridge, MA. | 1 years |
| Liselotte Hyveled | F | 58 | 29 years | |
| Alexis Michas | M | 66 |
Revvity BV
Revvity BV Medical SpecialtiesHealth Technology PerkinElmer focuses on improving the health and safety of people and the environment. The company is headquartered in Zaventem, Belgium. | 5 years |
| Ludovic Helfgott | M | 50 | 5 years | |
| Jayashree Kailas Thacker | F | - | 1 years | |
| Jane Buus Laursen | M | 49 | - | |
| Sergey Manelis | M | - | 4 years | |
| John Trainer | M | 50 |
Corvidia Therapeutics, Inc.
Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | - |
| Heidrun Irschik-Hadjieff | F | - |
Shire Orphan Therapies GmbH
Shire Orphan Therapies GmbH Pharmaceuticals: MajorHealth Technology Shire Orphan Therapies GmbH engages in the development, manufacture, and distribution of chemical and biochemical products, ingredients, as well as pharmaceutical and diagnostic products. The company was founded in 1994 and is headquartered in Berlin, Germany. | - |
| Camilla Soenderby | F | - |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | 3 years |
| Will West | M | - |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | - |
| Irina Ivanischeva | F | - | - | |
| Anita Gonzales | F | 48 | 1 years | |
| Martin Lange | M | 54 | 22 years | |
| Camilla Sylvest | F | 52 | 28 years | |
| Robin Evers | M | - | - | |
| Sophie Vandebroek | M | 62 | - | |
| Graham Hetherington | M | 65 |
Shire Orphan Therapies GmbH
Shire Orphan Therapies GmbH Pharmaceuticals: MajorHealth Technology Shire Orphan Therapies GmbH engages in the development, manufacture, and distribution of chemical and biochemical products, ingredients, as well as pharmaceutical and diagnostic products. The company was founded in 1994 and is headquartered in Berlin, Germany. | - |
| Naveed Iqbal Siddiqi | M | - |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | - |
| Klaus Stöckemann | M | - |
Shire Orphan Therapies GmbH
Shire Orphan Therapies GmbH Pharmaceuticals: MajorHealth Technology Shire Orphan Therapies GmbH engages in the development, manufacture, and distribution of chemical and biochemical products, ingredients, as well as pharmaceutical and diagnostic products. The company was founded in 1994 and is headquartered in Berlin, Germany. | - |
| Mike Birch | M | - |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | - |
| Simona Heidempergher | F | 56 |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | - |
| Tom Gadek | M | - |
Shire Orphan Therapies GmbH
Shire Orphan Therapies GmbH Pharmaceuticals: MajorHealth Technology Shire Orphan Therapies GmbH engages in the development, manufacture, and distribution of chemical and biochemical products, ingredients, as well as pharmaceutical and diagnostic products. The company was founded in 1994 and is headquartered in Berlin, Germany. | - |
| Katrine Sperling | F | - | 22 years | |
| Anderson Timothy | M | - |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | - |
| Mette Kruse Danielsen | F | - | - | |
| Tania Sabroe | F | 47 | 17 years | |
| Anne Margrethe Hauge | F | - | - | |
| Maziar Mike Doustdar | M | 54 | 32 years | |
| Paul Eisenberg | M | - |
Corvidia Therapeutics, Inc.
Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | - |
| Doug Langa | M | 58 | 13 years | |
| Stephen Gough | M | - | 9 years | |
| Magali Four | F | - | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Robert Friel | M | 68 | 20 years | |
| Michael Davidson | M | 67 |
Corvidia Therapeutics, Inc.
Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | 4 years |
| Robert J. de Vaere | M | 66 |
IDM Pharma, Inc.
 IDM Pharma, Inc. Pharmaceuticals: MajorHealth Technology IDM Pharma, Inc. develops products for the destruction of cancer cells. Its products activate the immune system or prevent recurrence by triggering adaptive immune response. The company was founded in established on October 1987 and is headquartered in Cambridge, MA. | 4 years |
| Michael Tomsicek | M | 58 | 5 years | |
| Timothy Walbert | M | 57 |
IDM Pharma, Inc.
IDM Pharma, Inc. Pharmaceuticals: MajorHealth Technology IDM Pharma, Inc. develops products for the destruction of cancer cells. Its products activate the immune system or prevent recurrence by triggering adaptive immune response. The company was founded in established on October 1987 and is headquartered in Cambridge, MA. | 2 years |
| Jakob Riis | M | 58 | 21 years | |
| Göran Albert Ando | M | 75 | 13 years | |
| Andrew Okun | M | 54 | 22 years | |
| Alphonse Galdes | M | 71 | - | |
| Rahul Kakkar | M | 49 |
Corvidia Therapeutics, Inc.
Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | 4 years |
| Jacques Turgeon | M | - |
Université Laval
| 9 years |
| Ram Aiyar | M | - |
Corvidia Therapeutics, Inc.
Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | 5 years |
| James Tobin | M | 79 | 5 years | |
| James Daly | M | 63 |
State University of New York at Buffalo
| 6 years |
| Jessica Moreno | F | - | - | |
| Brian Piekos | M | 49 | 5 years | |
| Timothy D. Hunt | M | - | 9 years | |
| Ben Harshbarger | M | 55 | 10 years | |
| Aaron H. Burstein | M | - |
State University of New York at Buffalo
| 7 years |
| Neil Leibman | M | 64 |
State University of New York at Buffalo
| 4 years |
| Paul Clancy | M | 62 | 16 years | |
| Tamara Joseph | F | 61 | 4 years | |
| Gaétan Duplain | M | - |
Université Laval
| 5 years |
| Bruno Francois Jules Angelici | M | 77 | 6 years | |
| Kåre Schultz | M | 62 | 26 years | |
| Mark Corrigan | M | 66 | 7 years | |
| Kenton Sicchitano | M | 79 | 16 years | |
| Jonathan M. Pfohl | M | 57 |
State University of New York at Buffalo
| 5 years |
| Christopher Guiffre | M | 56 | 7 years | |
| Margaret McGlynn | F | 64 |
State University of New York at Buffalo
| - |
| Lonnie Moulder | M | 66 | 5 years | |
| James L. Vincent | M | 84 | 12 years | |
| Lynn Schenk | F | 79 | 25 years | |
| Robert W. Pangia | M | 72 | 24 years | |
| Nancy Hutson | M | 74 | 7 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 52 | 52.00% |
| Denmark | 28 | 28.00% |
| United Kingdom | 11 | 11.00% |
| Belgium | 7 | 7.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Sylvie Grégoire
- Personal Network